8月8日 - ** 透皮制药产品制造商NutribandNTRB.O股价上涨3.5%至7.38美元
** Nutriband称FDA批准了该公司芬太尼贴片的会议申请
** 会议定于9月18日举行，监管机构将就该公司的芬太尼贴片上市申请提供反馈意见
** NTRB 正在开发 Aversa 专利技术，该技术可防止芬太尼等强效阿片类药物的滥用和误用，从而使透皮贴剂更加安全。
** 包括盘中走势在内，该股今年累计上涨 52.44
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.